Synopsis
Synopsis
0
KDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Allegron
2. Apo Nortriptyline
3. Apo-nortriptyline
4. Aventyl
5. Desitriptyline
6. Desmethylamitriptylin
7. Gen Nortriptyline
8. Gen-nortriptyline
9. Hydrochloride, Nortriptyline
10. Norfenazin
11. Nortrilen
12. Nortriptyline
13. Novo Nortriptyline
14. Novo-nortriptyline
15. Nu Nortriptyline
16. Nu-nortriptyline
17. Pamelor
18. Paxtibi
19. Pms Nortriptyline
20. Pms-nortriptyline
21. Ratio Nortriptyline
22. Ratio-nortriptyline
1. 894-71-3
2. Nortriptyline Hcl
3. Pamelor
4. Desmethylamitriptyline Hydrochloride
5. Allegron
6. Acetexa
7. Altilev
8. Nortriptyline (hydrochloride)
9. Nortrilen
10. Aventyl Hydrochloride
11. Sensival
12. Vividyl
13. Aventyl Allegron
14. Ateben Hydrochloride
15. Nortab Hydrochloride
16. Psychostyl
17. Nortriptylin Hydrochloride
18. Lilly 38489
19. Noramitriptyline Hydrochloride
20. Nortriptyline Monohydrochloride
21. Nsc-169453
22. 3-(10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5-ylidene)-n-methyl-1-propanamine Hydrochloride
23. Mls000069673
24. 00fn6ih15d
25. N 7048
26. Smr000058486
27. Pamelor Hydrochloride
28. 1-propanamine, 3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-n-methyl-, Hydrochloride
29. Nortriptylene Hydrochloride
30. Norzepine
31. 3-(10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-ylidene)-n-methylpropan-1-amine Hydrochloride
32. Wln: L C676 By&t&j Bu3m1 &gh
33. Nsc78248
34. Nortriptylinehydrochloride
35. Nsc169453
36. Sr-01000000223
37. Cas-894-71-3
38. Mfcd00058024
39. Unii-00fn6ih15d
40. 5-[3-(methylamino)propylidene]dibenzo[a,5]diene Hydrochloride
41. (2)10,d]cycloheptene-.delta.5.gamma.-propylamine, Hydrochloride
42. 5-[(3-(methylamino)propylidene]-10,d]cycloheptene Hydrochloride
43. 5h-dibenzo[a,.gamma.-propylamine, 10,11-dihydro-n-methyl-, Hydrochloride
44. 5h-dibenzo[a,.gamma.-propylamine, 10-11-dihydro-n-methyl-, Hydrochloride
45. 1-propanamine,11-dihydro-5h-dibenzo[a,d]cyclohepten-5-ylidene)-n-methyl-, Hydrochloride
46. Desitriptyline Hcl
47. 3-(5,6-dihydrodibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-n-methylpropan-1-amine;hydrochloride
48. Prestwick_366
49. Einecs 212-973-0
50. Pamelor (tn)
51. Nsc 78248
52. Nsc 169453
53. Cpd000058486
54. Elf-101 Hydrochloride
55. En-7048 Hydrochloride
56. Nortriptyline Hydrochloride [usan:usp:jan]
57. Opera_id_1915
58. Dsstox_cid_25109
59. Dsstox_rid_80676
60. Dsstox_gsid_45109
61. Schembl41329
62. Mls001077267
63. Mls002222206
64. Mls006010656
65. Chebi:7641
66. Chembl1201156
67. Dtxsid2045109
68. Regid_for_cid_441358
69. Hms1568d10
70. Nortriptyline Hydrochloride- Bio-x
71. Hy-b1417
72. Nortriptyline For System Suitability
73. Tox21_110048
74. Tox21_500868
75. Nsc-78248
76. S3698
77. 5-(3-(methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene Hydrochloride
78. Akos015889095
79. Ccg-212718
80. Cs-4913
81. Ks-1306
82. Lp00868
83. Nc00522
84. 10,11-dihydro-5-(n-methyl-3-aminopropylidene)-5h-dibenzo[a,d]cycloheptene Hydrochloride
85. 5-(3-methylaminopropylidene)-10,11-dihydro-5h-dibenzo(a,d)cycloheptene Hydrochloride
86. Nortriptyline Hydrochloride [mi]
87. Ncgc00014483-01
88. Ncgc00094192-01
89. Ncgc00094192-02
90. Ncgc00261553-01
91. Nortriptyline Hydrochloride [jan]
92. 10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta(sup 5,gamma)-propylamine Hydrochloride
93. Bn164160
94. Nortriptyline Hydrochloride [hsdb]
95. Nortriptyline Hydrochloride [usan]
96. Nortriptyline Hydrochloride [mart.]
97. Nortriptyline Hydrochloride [vandf]
98. Nortriptyline Hydrochloride [usp-rs]
99. Nortriptyline Hydrochloride [who-dd]
100. Eu-0100868
101. Ft-0673146
102. Ft-0673147
103. N0957
104. Nortriptyline Hydrochloride (jp17/usp/inn)
105. En300-26665
106. D00816
107. F19641
108. N 7261
109. Nortriptyline Hydrochloride [orange Book]
110. Nortriptyline Hydrochloride [ep Monograph]
111. Nortriptyline Hydrochloride [usp Monograph]
112. Nortriptyline Hydrochloride, >=98% (tlc), Powder
113. Sr-01000000223-2
114. Sr-01000000223-7
115. W-109609
116. Q27231345
117. Nortriptyline Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
118. Nortriptyline Hydrochloride, British Pharmacopoeia (bp) Reference Standard
119. Nortriptyline Hydrochloride, European Pharmacopoeia (ep) Reference Standard
120. 3-(10,11-2h-5h-dibenzo[a,d][7]annulen-5-ylidene)-n-methyl-1-propanaminium Chloride
121. 3-(10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-ylidene)-n-methylpropan-1-aminehydrochloride
122. Nortriptyline For System Suitability, European Pharmacopoeia (ep) Reference Standard
123. Nortriptyline Hydrochloride, United States Pharmacopeia (usp) Reference Standard
124. 10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-d(sup5,.gamma.)-propylamine Hydrochloride
125. 1001637-77-9
126. 5h-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10-11-dihydro-n-methyl-, Hydrochloride
127. Nortriptyline Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 299.8 g/mol |
---|---|
Molecular Formula | C19H22ClN |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 3 |
Exact Mass | 299.1440774 g/mol |
Monoisotopic Mass | 299.1440774 g/mol |
Topological Polar Surface Area | 12 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 307 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Nortriptyline hydrochloride |
PubMed Health | Nortriptyline (By mouth) |
Drug Classes | Antidepressant |
Drug Label | Nortriptyline hydrochloride is 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-, hydrochloride. The structural formula is represented below:C19H21NHCl M.W. 299.84Nortriptyline Hydrochloride Capsules USP (equivalent to 1... |
Active Ingredient | Nortriptyline hydrochloride |
Dosage Form | Capsule; Solution |
Route | Oral |
Strength | eq 50mg base; eq 75mg base; eq 10mg base/5ml; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Teva; Pharm Assoc; Taro; Watson Labs; Mylan |
2 of 4 | |
---|---|
Drug Name | Pamelor |
Drug Label | Pamelor (nortriptyline HCl) is 1-propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5-ylidene)-N-methyl-, hydrochloride.The structural formula is as follows:... |
Active Ingredient | Nortriptyline hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 75mg base; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Mallinckrodt |
3 of 4 | |
---|---|
Drug Name | Nortriptyline hydrochloride |
PubMed Health | Nortriptyline (By mouth) |
Drug Classes | Antidepressant |
Drug Label | Nortriptyline hydrochloride is 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-, hydrochloride. The structural formula is represented below:C19H21NHCl M.W. 299.84Nortriptyline Hydrochloride Capsules USP (equivalent to 1... |
Active Ingredient | Nortriptyline hydrochloride |
Dosage Form | Capsule; Solution |
Route | Oral |
Strength | eq 50mg base; eq 75mg base; eq 10mg base/5ml; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Teva; Pharm Assoc; Taro; Watson Labs; Mylan |
4 of 4 | |
---|---|
Drug Name | Pamelor |
Drug Label | Pamelor (nortriptyline HCl) is 1-propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5-ylidene)-N-methyl-, hydrochloride.The structural formula is as follows:... |
Active Ingredient | Nortriptyline hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 75mg base; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Mallinckrodt |
Antidepressive Agents, Tricyclic
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)
Adrenergic Uptake Inhibitors
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-10-23
Pay. Date : 2023-08-08
DMF Number : 33227
Submission : 2018-09-29
Status : Active
Type : II
Certificate Number : CEP 2014-032 - Rev 02
Issue Date : 2024-06-28
Type : Chemical
Substance Number : 941
Status : Valid
Date of Issue : 2020-02-14
Valid Till : 2022-07-28
Written Confirmation Number : WC-0445A1
Address of the Firm :
NDC Package Code : 71554-011
Start Marketing Date : 2019-04-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21330
Submission : 2008-01-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7414
Submission : 1988-03-30
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-05-20
Pay. Date : 2019-01-28
DMF Number : 31974
Submission : 2017-09-08
Status : Active
Type : II
Certificate Number : R1-CEP 2017-066 - Rev 00
Issue Date : 2023-07-31
Type : Chemical
Substance Number : 941
Status : Valid
Date of Issue : 2021-05-11
Valid Till : 2024-04-16
Written Confirmation Number : WC-0287n
Address of the Firm :
NDC Package Code : 66577-025
Start Marketing Date : 1984-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-12-28
Pay. Date : 2015-04-09
DMF Number : 7846
Submission : 1988-12-29
Status : Active
Type : II
Registration Number : 219MF10264
Registrant's Address : Via Bissone, 5, 20021-Baranzate, Milano, Italy
Initial Date of Registration : 2007-08-16
Latest Date of Registration : --
NDC Package Code : 46438-0049
Start Marketing Date : 2012-03-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25380
Submission : 2011-10-07
Status : Inactive
Type : II
Certificate Number : CEP 2006-026 - Rev 02
Issue Date : 2023-10-19
Type : Chemical
Substance Number : 941
Status : Valid
Date of Issue : 2022-06-08
Valid Till : 2025-06-25
Written Confirmation Number : WC-0107
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3291
Submission : 1978-09-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2890
Submission : 1977-03-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21330
Submission : 2008-01-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25380
Submission : 2011-10-07
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-12-28
Pay. Date : 2015-04-09
DMF Number : 7846
Submission : 1988-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2891
Submission : 1977-03-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2890
Submission : 1977-03-18
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-10-23
Pay. Date : 2023-08-08
DMF Number : 33227
Submission : 2018-09-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7414
Submission : 1988-03-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3291
Submission : 1978-09-15
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-05-20
Pay. Date : 2019-01-28
DMF Number : 31974
Submission : 2017-09-08
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8143
Submission : 1989-07-26
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?